KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
Open Access
- 22 June 2009
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 9 (1), 196
- https://doi.org/10.1186/1471-2407-9-196
Abstract
Glioblastomas (GBM) are typically comprised of morphologically diverse cells. Despite current advances in therapy, including surgical resection followed by radiation and chemotherapy, the prognosis for patients with GBM remains poor. Unfortunately, most patients die within 2 years of diagnosis of their disease. Molecular abnormalities vary among individual patients and also within each tumor. Indeed, one of the distinguishing features of GBM is its marked genetic heterogeneity. Due to the brain location of the tumor, the potential target inhibition for anticancer therapy must exhibit a manageable neurotoxicity profile in the concentration range in which the compounds show anti-proliferative activity.Kinesin KIF11 inhibition by small molecules such as Monastrol or Ispinesib is currently under investigation in the field of malignant tumors. In the current study we have assessed the relevance of the anti-mitotic Kinesin-like protein KIF11 in human GBM cell-lines. In this study the target was validated using a set of well characterised and potentially specific small molecule inhibitors of KIF11: an ispinesib analog, Monastrol, a Merck compound and 3 simplified derivatives of the Merck compound. Following an in silico selection, those compounds predicted to bear a favorable BBB permeation profile were assessed for their phenotypic effect on cell lines derived both from primary (U87MG) as well as treated (DBTRG-05-MG) glioblastomas. For some compounds, these data could be compared to their effect on normal human astrocytes, as well as their neurotoxicity on primary rat cortical neurons. The ispinesib analogue 1 showed an anti-proliferative effect on GBM cell lines by blocking them in the G2/M phase in a concentration range which was shown to be harmless to primary rat cortical neurons. Furthermore, ispinesib analog increased caspase 3/7-induced apoptosis in U87MG cells. In the area of cell cycle inhibition, KIF11 is critical for proper spindle assembly and represents an attractive anticancer target. Our results suggest that KIF11 inhibitors, when able to permeate the blood-brain-barrier, could represent an interesting class of anticancer drugs with low neurotoxic effects in the treatment of brain tumors.Keywords
This publication has 27 references indexed in Scilit:
- New movements in neurofilament transport, turnover and diseaseExperimental Cell Research, 2007
- An Inhibitor of the Kinesin Spindle Protein Activates the Intrinsic Apoptotic Pathway Independently of p53 and De Novo Protein SynthesisMolecular and Cellular Biology, 2007
- Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSPBioorganic & Medicinal Chemistry Letters, 2006
- Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug DevelopmentCancer Research, 2006
- Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell deathCancer Cell, 2005
- Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippageCancer Cell, 2005
- Identification of the Protein Binding Region of S-Trityl-l-cysteine, a New Potent Inhibitor of the Mitotic Kinesin Eg5Biochemistry, 2004
- Malignant glioma: genetics and biology of a grave matterGenes & Development, 2001
- THE DESIGN PLAN OF KINESIN MOTORSAnnual Review of Cell and Developmental Biology, 1997
- Hydrogen Bonding. 33. Factors That Influence the Distribution of Solutes between Blood and BrainJournal of Pharmaceutical Sciences, 1994